What is Versartis' stock symbol?
Versartis trades on the NASDAQ under the ticker symbol "VSAR."
Where is Versartis' stock going? Where will Versartis' stock price be in 2017?
7 brokers have issued twelve-month price objectives for Versartis' shares. Their forecasts range from $20.00 to $28.00. On average, they expect Versartis' stock price to reach $23.60 in the next year.
When will Versartis announce their earnings?
Versartis is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.
What are analysts saying about Versartis stock?
Here are some recent quotes from research analysts about Versartis stock:
According to Zacks Investment Research, "Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. " (1/12/2017)
Credit Suisse Group analysts commented, "We are incrementally more optimistic on the VSAR story following last week’s Investor Symposium given the progress the company is making for the well-discussed pediatric indication and also because of what may be an underappreciated opportunity in the adult indication. The stock has had a relatively volatile 12 months (along with much of SMID cap pharma/biotech), but as we start looking ahead to 2017 we see the company as potentially better positioned with the phase 3 data readout in pediatric growth hormone deficiency (GHD) that is expected in 3Q 2017 being the key value driver. The recent Teijen collaboration also puts VSAR in a more secure financial position to see things through on both the pediatric and adult side." (9/19/2016)
Who owns Versartis stock?
Versartis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (11.94%), FMR LLC (11.86%), New Leaf Venture Partners L.L.C. (5.86%), Federated Investors Inc. PA (4.23%), Kingdon Capital Management L.L.C. (1.47%) and State Street Corp (1.28%). Company insiders that own Versartis stock include Edmon R Jennings, Jay Shepard, Jeffrey L Cleland, John Varian, Joshua T Brumm, Paul Westberg, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju.
Who sold Versartis stock? Who is selling Versartis stock?
Versartis' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Dimensional Fund Advisors LP. Company insiders that have sold Versartis stock in the last year include Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm and Paul Westberg.
Who bought Versartis stock? Who is buying Versartis stock?
Versartis' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, New Leaf Venture Partners L.L.C., Arrowpoint Asset Management LLC, State Street Corp, FMR LLC, Kingdon Capital Management L.L.C., Renaissance Technologies LLC and A.R.T. Advisors LLC. Company insiders that have bought Versartis stock in the last two years include Joshua T Brumm, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju.
How do I buy Versartis stock?
Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Versartis stock cost?
One share of Versartis stock can currently be purchased for approximately $16.35.